StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) stock

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Earnings

Johnson & Johnson's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 20, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$25.40B
+5.8% on a year earlier
adjusted EPS*, Q3 FY2026
$2.59
$2.80 a year earlier
Latest guidance
Issued
Oct 13, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Johnson & Johnson's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 28, 2026Jan 20, 2027Expected–––––
Q3 FY2026ended Sep 28, 2026Oct 13, 2026before the open$25.40B+5.8%$0.09$2.59Release
Q2 FY2026ended Jun 28, 2026Jul 15, 2026before the open––––Release
Q1 FY2026ended Mar 29, 2026Apr 14, 2026before the open$24.06B+9.9%$2.14$2.70Release
Q4 FY2025ended Dec 28, 2025Jan 21, 2026before the open$24.60B+9.3%$2.10$2.46Release
Q3 FY2025ended Sep 28, 2025Oct 14, 2025before the open$24.00B+6.7%$2.12$2.80Release
Q2 FY2025ended Jun 29, 2025Jul 16, 2025before the open$23.74B+6.0%$2.29$2.77Release
Q1 FY2025ended Mar 30, 2025Apr 15, 2025before the open$21.89B+2.3%$4.54$2.77Release
Q4 FY2024ended Dec 29, 2024Jan 22, 2025before the open$22.50B+5.1%$1.41$2.04Release
Q3 FY2024ended Sep 29, 2024Oct 15, 2024before the open$22.50B+5.1%$1.11$2.42Release
Q2 FY2024ended Jun 30, 2024Jul 17, 2024before the open$22.40B-12.2%$1.93$2.82Release
Q1 FY2024ended Mar 31, 2024Apr 16, 2024before the open$21.40B-13.4%$2.20$2.71Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Johnson & Johnson's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Estimated Reported SalesGAAPFY2026$101.00B – $101.40B–NewOct 13, 2026
Estimated Reported Salesnon-GAAPFY2026$100.30B – $101.30B–NewApr 14, 2026
Estimated Reported SalesGAAPFY2026$100.00B – $101.00B–NewJan 21, 2026
Adjusted EPS (Diluted)non-GAAPFY2026$11.05 – $11.15–NewOct 13, 2026
Adjusted EPS (Diluted)non-GAAPFY2026$11.45 – $11.65$11.43 – $11.63RaisedApr 14, 2026
Adjusted EPS (Diluted) Change vs. Prior Yearnon-GAAPFY2026+7.5% – +8.9%–RaisedJul 15, 2026
Adjusted Operational EPS (Diluted) Change vs. Prior Yearnon-GAAPFY2026+6.6% – +8%–ReaffirmedJul 15, 2026
Estimated Reported Sales Change vs. Prior Yearnon-GAAPFY2026+7% – +7.6%–RaisedJul 15, 2026
Operational Sales Change vs. Prior Yearnon-GAAPFY2026+6.5% – +7.1%–NewJul 15, 2026

Guidance vs results

The last range Johnson & Johnson gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted Operational EPS (Diluted)$10.63 – $10.73$10.80Σ4QAbove range
FY2025Revenue$93.00B – $93.40B$94.24BΣ4QAbove range
FY2025Revenue growth+3.5% – +4%+6.12%Σ4QAbove range

Guidance history

Every forecast Johnson & Johnson put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 13, 2026Adjusted EPS (Diluted)FY2026$11.05 – $11.15New
Oct 13, 2026Estimated Reported SalesFY2026$101.00B – $101.40BNew
Jul 15, 2026Adjusted Operational EPS (Diluted) Change vs. Prior YearFY2026+6.6% – +8%Reaffirmed
Jul 15, 2026Adjusted EPS (Diluted) Change vs. Prior YearFY2026+7.5% – +8.9%Raised
Jul 15, 2026Estimated Reported Sales Change vs. Prior YearFY2026+7% – +7.6%Raised
Jul 15, 2026Operational Sales Change vs. Prior YearFY2026+6.5% – +7.1%New
Apr 14, 2026Adjusted EPS (Diluted)FY2026$11.45 – $11.65Raised
Apr 14, 2026Estimated Reported SalesFY2026$100.30B – $101.30BNew
Jan 21, 2026Adjusted EPS (Diluted)FY2026$11.43 – $11.63New
Jan 21, 2026Estimated Reported SalesFY2026$100.00B – $101.00BNew
Oct 14, 2025Adjusted Operational EPS (Diluted)FY2025$10.63 – $10.73Lowered
Oct 14, 2025Adjusted EPS (Diluted)FY2025$10.80 – $10.90Raised
Oct 14, 2025Operational SalesFY2025$93.00B – $93.40BLowered
Oct 14, 2025Estimated Reported SalesFY2025$93.50B – $93.90BRaised
Oct 14, 2025Adjusted Operational SalesFY2025+3.5% – +4%New
Jul 16, 2025Adjusted EPS (Diluted)FY2025$10.80 – $10.90New
Jul 16, 2025Estimated Reported SalesFY2025$93.20B – $93.60BNew
Apr 15, 2025Adjusted Operational Sales Change vs. Prior YearFY2025+2% – +3%New
Jan 22, 2025Adjusted Operational EPS (Diluted)FY2025$10.75 – $10.95New
Jan 22, 2025Adjusted EPS (Diluted)FY2025$10.50 – $10.70Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Johnson & Johnson filed with the SEC as exhibits to Form 8-K or 6-K

  1. Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
    Results
  2. Johnson & Johnson and subsidiaries
    Results
  3. Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
    Update
  4. Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
    Update
  5. FOR RELEASE AT 6:15PM ET
    Update
  6. Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
    Results
  7. Johnson & Johnson and subsidiaries
    Results
  8. Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
    Results
  9. Johnson & Johnson and subsidiaries
    Results
  10. Johnson & Johnson Announces 64 th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
    Results
  11. Johnson & Johnson reports Q4 and Full-Year 2025 results
    Results
  12. Johnson & Johnson and subsidiaries
    Results
  13. Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook
    Results
  14. Johnson & Johnson and subsidiaries
    Results
  15. Johnson & Johnson announces intent to separate its Orthopaedics business
    Results